U.S. signs agreement with AstraZeneca for development and supply of COVID-19 antibody treatment |
Clinical News
eMediNexus Coverage from: 
U.S. signs agreement with AstraZeneca for development and supply of COVID-19 antibody treatment

0 Read Comments                

The U.S. government has signed an agreement with AstraZeneca Plc AZN.L for the development and supply of around 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that has been used for the treatment of President Donald Trump.

Funding will be provided to AstraZeneca by the U.S. health agency for two Phase 3 clinical trials under operation Warp Speed.The operation aims to expedite treatments and vaccines for COVID-19.

One of the trials will assess the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in nearly 5,000 participants, while the second one will investigate post-exposure preventative and pre-emptive treatment in around 1,100 participants… (Reuters, October 10, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now